Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials
Options
BORIS DOI
Date of Publication
2010
Publication Type
Article
Division/Institute
Author
Mitchell, Paul | |
Korobelnik, Jean-François | |
Lanzetta, P | |
Holz, Frank G | |
Prunte, Christian | |
Schmidt-Erfurth, Ursula Margarethe | |
Tano, Yasuo |
Subject(s)
Series
British journal of ophthalmology
ISSN or ISBN (if monograph)
0007-1161
Publisher
BMJ Publishing Group
Language
English
Publisher DOI
PubMed ID
19443462
Description
BACKGROUND:
Neovascular age-related macular degeneration (AMD) has a poor prognosis if left untreated, frequently resulting in legal blindness. Ranibizumab is approved for treating neovascular AMD. However, further guidance is needed to assist ophthalmologists in clinical practice to optimise treatment outcomes.
METHODS:
An international retina expert panel assessed evidence available from prospective, multicentre studies evaluating different ranibizumab treatment schedules (ANCHOR, MARINA, PIER, SAILOR, SUSTAIN and EXCITE) and a literature search to generate evidence-based and consensus recommendations for treatment indication and assessment, retreatment and monitoring.
RESULTS:
Ranibizumab is indicated for choroidal neovascular lesions with active disease, the clinical parameters of which are outlined. Treatment initiation with three consecutive monthly injections, followed by continued monthly injections, has provided the best visual-acuity outcomes in pivotal clinical trials. If continued monthly injections are not feasible after initiation, a flexible strategy appears viable, with monthly monitoring of lesion activity recommended. Initiation regimens of fewer than three injections have not been assessed. Continuous careful monitoring with flexible retreatment may help avoid vision loss recurring. Standardised biomarkers need to be determined.
CONCLUSION:
Evidence-based guidelines will help to optimise treatment outcomes with ranibizumab in neovascular AMD.
Neovascular age-related macular degeneration (AMD) has a poor prognosis if left untreated, frequently resulting in legal blindness. Ranibizumab is approved for treating neovascular AMD. However, further guidance is needed to assist ophthalmologists in clinical practice to optimise treatment outcomes.
METHODS:
An international retina expert panel assessed evidence available from prospective, multicentre studies evaluating different ranibizumab treatment schedules (ANCHOR, MARINA, PIER, SAILOR, SUSTAIN and EXCITE) and a literature search to generate evidence-based and consensus recommendations for treatment indication and assessment, retreatment and monitoring.
RESULTS:
Ranibizumab is indicated for choroidal neovascular lesions with active disease, the clinical parameters of which are outlined. Treatment initiation with three consecutive monthly injections, followed by continued monthly injections, has provided the best visual-acuity outcomes in pivotal clinical trials. If continued monthly injections are not feasible after initiation, a flexible strategy appears viable, with monthly monitoring of lesion activity recommended. Initiation regimens of fewer than three injections have not been assessed. Continuous careful monitoring with flexible retreatment may help avoid vision loss recurring. Standardised biomarkers need to be determined.
CONCLUSION:
Evidence-based guidelines will help to optimise treatment outcomes with ranibizumab in neovascular AMD.
File(s)
| File | File Type | Format | Size | License | Publisher/Copright statement | Content | |
|---|---|---|---|---|---|---|---|
| 3.pdf | text | Adobe PDF | 674.33 KB | publisher | published |